This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Cubist Focuses On Expanded Antibiotic Pipeline To Combat Infectious Diseases At IDWeek 2013

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will focus on its expanded pipeline of antibiotics, represented through several presentations, during IDWeek 2013 being held October 2-6 in San Francisco. Presentations will feature the company’s development of antibiotics for serious infections caused by multidrug-resistant bacteria. Several presentations will also highlight the marketed antibiotic CUBICIN® (daptomycin for injection).

Presentations at IDWeek will focus on the company’s late stage candidates ceftolozane/tazobactam (formerly CXA-201) being studied for the treatment of Gram-negative bacteria and surotomycin (formerly CB-183,815) being studied for the treatment of diarrhea caused by Clostridium difficile (C. difficile), categorized as an urgent threat in the recent U.S. Centers for Disease Control and Prevention (CDC) report “Antibiotic Resistant Threats in the United States, 2013.” Presentations will also feature tedizolid phosphate, a once daily, I.V. or orally administered oxazolidinone being developed for the treatment of serious Gram-positive skin infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). In addition, Cubist expects to begin trials with tedizolid phosphate in gram-positive lung infections later this year. Cubist has added tedizolid to its pipeline through the recent acquisition of Trius Therapeutics. All of these candidates have been granted Fast Track status, pursuant to the GAIN Act, by the U.S. Food and Drug Administration (FDA) for their respective Qualified Infectious Disease Product (QIDP) indications.

“With the recent acquisition of Trius, Cubist is making significant traction towards meeting the IDSA challenge to industry and policy makers to develop and approve 10 new antibiotics by 2020. We are keenly focused on combatting growing antibacterial resistance and rising hospital-acquired infections,” said Steven Gilman, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer of Cubist Pharmaceuticals. “Our presentations will focus on our expanded pipeline, which includes antibiotics being developed to address pathogens contributing to the escalating global public health threat. During IDWeek we are also marking the 10 year anniversary of CUBICIN, which was developed and launched by Cubist.”

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs